Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: An Israeli population-based case-control study

Journal of the National Cancer Institute

Volumn 95, Issue 14, 2003, Pages 1072-1078

  Rutter, Joni L ^a   Wacholder, Sholom ^a   Chetrit, Angela ^b   Lubin, Flora ^b   Menczer, Joseph ^c   Ebbers, Sarah ^a   Tucker, Margaret A ^a   Struewing, Jeffery P ^a   Hartge, Patricia ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; GYNECOLOGIC SURGERY; HETEROZYGOTE DETECTION; HUMAN; ISRAEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OVARIECTOMY; OVARY CANCER; PATIENT SELECTION; PERITONEUM CANCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; CARCINOMA; CLINICAL TRIAL; FOUNDER EFFECT; GENETICS; HETEROZYGOTE; JEW; MIDDLE AGED; MULTICENTER STUDY; MUTATION; OVARY TUMOR; PERITONEUM TUMOR; RISK; STATISTICAL MODEL; STATISTICS; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CARCINOMA; FEMALE; FOUNDER EFFECT; GENES, BRCA1; GENES, BRCA2; GYNECOLOGIC SURGICAL PROCEDURES; HETEROZYGOTE; HUMANS; ISRAEL; JEWS; LOGISTIC MODELS; MIDDLE AGED; MUTATION; ODDS RATIO; OVARIAN NEOPLASMS; OVARIECTOMY; PERITONEAL NEOPLASMS; RISK ASSESSMENT;

EID: 0042767641     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.14.1072     Document Type: Article

References (36)

1. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
2. McGowan L, Norris HJ, Hartge P, Hoover R, Lesher L. Risk factors in ovarian cancer. Eur J Gynaecol Oncol 1988;9:195-9.
3. Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. Cancer 1993;71:566-72.
4. Struewing JP, Hartge P, Wacholder S, Baker BS, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
5. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
6. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
7. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
8. Liede A, Karlan BY, Baldwin RL, Platt LD, Kuperstein G, Narod SA. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 2002;20:1570-7.
9. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and non-carriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235-40.
10. Lubin F, Chetrit A, Freedman LS, Alfandary E, Fishler Y, Nitzan H, et al. Body mass index at age 18 years and during adult life and ovarian cancer risk. Am J Epidemiol 2003;157:113-20.
11. Menczer J, Chetrit A, Barda G, Lubin F, Fishler Y, Altaras M, et al. Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women. Gynecol Oncol 2003;88:58-61.
12. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer: a prospective study. JAMA 1993;270:2813-8.
13. Irwin KL, Wingo PA, Lee NC. Agreement of self-reported ovarian number following gynecologic surgery with medical record reports. J Clin Epidemiol 1990;43:181-9.
14. Albert PS, Ratnasinghe D, Tangrea J, Wacholder S. Limitations of the case-only design for identifying gene-environment interactions. Am J Epidemiol 2001;154:687-93.
15. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Available at: http://www.seer.cancer.gov. [Last accessed: May 28, 2003].
16. Piek JM, van Diest PJ, Zweemer RP, Kenemans P, Verheijen RH. Re: Tubal ligation and risk of ovarian cancer. Lancet 2001;358:844.
17. Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni JF. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982;2:795-7.
18. Karlan BY, Baldwin RL, Lopez-Luevanos E, Raffel LJ, Barbuto D, Narod S, et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999;180:917-28.
19. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997;15:103-5.
20. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 and BRCA2 mutations: a case-control study. Lancet 2001;357:1467-70.
21. Kauff ND, Perez-Segura P, Robson ME, Scheuer L, Siegel B, Schluger A, et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high-risk Ashkenazi breast and ovarian cancer families. J Med Genet 2002;39:611-4.
22. Irwin KL, Weiss NS, Lee NC, Peterson HB. Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol 1991;134:362-9.
23. Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M, et al. Tubal sterilization, hysterectomy and decreased risk of ovarian cancer. Int J Cancer 1997;71:948-51.
24. Kreiger N, Sloan M, Cotterchio M, Parsons P. Surgical procedures associated with risk of ovarian cancer. Int J Epidemiol 1997;26:710-5.
25. Miracle-McMahill HL, Calle EE, Kosinski AS, Rodriguez C, Wingo PA, Thun MJ, et al. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am J Epidemiol 1997;145:349-57.
26. Neil JR, Hammond GI, Noble AD. Late complications of sterilization by laparoscopy and tubal ligation. Lancet 1975;2:699-700.
27. Janson PO, Jansson I. The acute effect of hysterectomy on ovarian blood flow. Am J Obstet Gynecol 1977;127:349-52.
28. DeStefano F, Perlman JA, Peterson HB, Diamond EL. Long-term risk of menstrual disturbances after tubal sterilization. Am J Obstet Gynecol 1985; 152:835-41.
29. Cattanach J. Oestrogen deficiency after tubal ligation. Lancet 1985:1: 847-9.
30. Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol (Oxf.) 1998; 49:695-707.
31. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91:1459-67.
32. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998;339:424-8.
33. Kreiger N, Sloan M, Cotterchio M, Kirsh V. The risk of breast cancer following reproductive surgery. Eur J Cancer 1999;35:97-101.
34. Brinton LA, Gammon MD, Coates RJ, Hoover RN. Tubal ligation and risk of breast cancer. Br J Cancer 2000;82:1600-4.
35. Barrett-Connor E. Hormone replacement therapy. BMJ 1998;317:457-61.
36. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-9.